Sean Godbout's Insider Trades & SAST Disclosures

Sean Godbout's most recent trade in Biogen Inc was a trade of 181 Common Stock done . Disclosure was reported to the exchange on April 1, 2026.

Share

Note

This is a custom search result for pattern Sean Godbout.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.

All Superstars

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	01 Apr 2026	181	1,395 (0%)	0%		0	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	01 Apr 2026	181	364	-		-	Restricted Stock Unit
Biogen	Sean Godbout	Chief Accounting Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 183.78 per share.	01 Apr 2026	54	1,341 (0%)	0%	183.8	9,924	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Feb 2026	1,800	1,800	-		-	Restricted Stock Unit
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	06 Feb 2026	517	1,394 (0%)	0%		0	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	06 Feb 2026	517	1,035	-		-	Restricted Stock Unit
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	06 Feb 2026	305	305	-		-	Restricted Stock Unit
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	06 Feb 2026	305	980 (0%)	0%		0	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	06 Feb 2026	257	751 (0%)	0%		0	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	06 Feb 2026	257	0	-		-	Restricted Stock Unit
Biogen	Sean Godbout	Chief Accounting Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 201.18 per share.	06 Feb 2026	180	1,214 (0%)	0%	201.2	36,212	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 201.18 per share.	06 Feb 2026	103	877 (0%)	0%	201.2	20,722	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 201.18 per share.	06 Feb 2026	76	675 (0%)	0%	201.2	15,290	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	02 Oct 2025	26	27	-		-	Restricted Stock Unit
Biogen	Sean Godbout	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	02 Oct 2025	26	502 (0%)	0%		0	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.25 per share.	02 Oct 2025	8	494 (0%)	0%	155.3	1,242	Common Stock
Biogen	Sean Godbout	Chief Accounting Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Apr 2025	545	545	-		-	Restricted Stock Unit

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades